Research Analysts Issue Forecasts for AVTE FY2029 Earnings

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) – Wedbush issued their FY2029 earnings per share (EPS) estimates for Aerovate Therapeutics in a research report issued to clients and investors on Monday, February 24th. Wedbush analyst L. Chico expects that the company will post earnings per share of ($0.74) for the year. The consensus estimate for Aerovate Therapeutics’ current full-year earnings is ($2.64) per share.

Aerovate Therapeutics Trading Down 0.8 %

Shares of NASDAQ:AVTE opened at $2.41 on Wednesday. Aerovate Therapeutics has a 12-month low of $1.25 and a 12-month high of $32.42. The business has a 50 day moving average of $2.54 and a two-hundred day moving average of $2.34. The company has a market capitalization of $69.59 million, a PE ratio of -0.81 and a beta of 0.99.

Institutional Trading of Aerovate Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AVTE. Braidwell LP acquired a new position in shares of Aerovate Therapeutics in the fourth quarter worth about $3,817,000. Allostery Investments LP purchased a new position in shares of Aerovate Therapeutics in the 4th quarter valued at about $2,254,000. ADAR1 Capital Management LLC raised its holdings in Aerovate Therapeutics by 720.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company’s stock worth $2,459,000 after purchasing an additional 814,941 shares during the period. Jefferies Financial Group Inc. acquired a new position in Aerovate Therapeutics in the 4th quarter worth about $1,590,000. Finally, Blackstone Inc. purchased a new position in Aerovate Therapeutics during the fourth quarter worth approximately $1,324,000.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.